Why the study?
Does intravenous Ig (IVIg) inhibit the binding of anti-GM1 antibodies to their target antigen in sera from patients with neuropathies?
Does intravenous Ig (IVIg) inhibit the binding of anti-GM1 antibodies to their target antigen in sera from patients with neuropathies?
IVIg dose-dependently inhibits the binding of anti-GM1 antibodies to their target antigen, providing a possible mechanism for its clinical efficacy in motor neuropathies.
In this study, we preincubated the sera of 3 patients with neuropathies associated with elevated titers of IgM anti-GM1 antibodies, with increasing concentrations of intravenous Ig (IVIg) and assayed the inhibitory effect of this mixture on antibody binding to immobilized GM1 by an enzyme-linked immunosorbent assay. Pharmacologic concentrations of IVIg, ranging from 0.1 microgram/ml to 100 mg/ml, inhibited anti-GM1 binding to its target antigen from 26 +/- 3 to 71 +/- 7%, respectively, in a dose-dependent manner. A similar inhibition of binding was also observed with IVIg F(ab')2 fragments. These findings provide a possible mechanism for the clinical efficacy of IVIg in motor neuropathies.
No takes yet. Share an insight, caveat, or question.
Malik et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: